iX Biopharma Ltd. 42C.SI Stock
iX Biopharma Ltd. Price Chart
iX Biopharma Ltd. 42C.SI Financial and Trading Overview
iX Biopharma Ltd. stock price | 0.04 SGD |
Previous Close | 0.09 SGD |
Open | 0.09 SGD |
Bid | 0.09 SGD x 0 |
Ask | 0.09 SGD x 0 |
Day's Range | 0.09 - 0.09 SGD |
52 Week Range | 0.08 - 0.18 SGD |
Volume | 400 SGD |
Avg. Volume | 66.52K SGD |
Market Cap | 72.03M SGD |
Beta (5Y Monthly) | 0.875095 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.01 SGD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
42C.SI Valuation Measures
Enterprise Value | 64.46M SGD |
Trailing P/E | N/A |
Forward P/E | -9.4 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 19.296062 |
Price/Book (mrq) | 4.0869565 |
Enterprise Value/Revenue | 17.269 |
Enterprise Value/EBITDA | -6.514 |
Trading Information
iX Biopharma Ltd. Stock Price History
Beta (5Y Monthly) | 0.875095 |
52-Week Change | -45.97% |
S&P500 52-Week Change | 20.43% |
52 Week High | 0.18 SGD |
52 Week Low | 0.08 SGD |
50-Day Moving Average | 0.09 SGD |
200-Day Moving Average | 0.11 SGD |
42C.SI Share Statistics
Avg. Volume (3 month) | 66.52K SGD |
Avg. Daily Volume (10-Days) | 87.57K SGD |
Shares Outstanding | 766.3M |
Float | 521.75M |
Short Ratio | N/A |
% Held by Insiders | 46.88% |
% Held by Institutions | 1.08% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | June 30, 2022 |
Most Recent Quarter (mrq) | December 31, 2022 |
Next Fiscal Year End | June 30, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | -281.22% |
Gross Margin | 28.23% |
EBITDA Margin | -265.12% |
Management Effectiveness
Return on Assets (ttm) | -21.18% |
Return on Equity (ttm) | -70.82% |
Income Statement
Revenue (ttm) | 3.73M SGD |
Revenue Per Share (ttm) | 0.005 SGD |
Quarterly Revenue Growth (yoy) | -80.80% |
Gross Profit (ttm) | 12.29M SGD |
EBITDA | -9897000 SGD |
Net Income Avi to Common (ttm) | -15609000 SGD |
Diluted EPS (ttm) | -0.02 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 11.29M SGD |
Total Cash Per Share (mrq) | 0.02 SGD |
Total Debt (mrq) | 3.73M SGD |
Total Debt/Equity (mrq) | 21.56 SGD |
Current Ratio (mrq) | 1.909 |
Book Value Per Share (mrq) | 0.023 |
Cash Flow Statement
Operating Cash Flow (ttm) | -6514000 SGD |
Levered Free Cash Flow (ttm) | -4343250 SGD |
Profile of iX Biopharma Ltd.
Country | Singapore |
State | N/A |
City | Singapore |
Address | No. 14-01 Great World City East Lobby |
ZIP | 237994 |
Phone | 65 6235 2270 |
Website | https://www.ixbiopharma.com |
Industry | Drug Manufacturers-Specialty & Generic |
Sector(s) | Healthcare |
Full Time Employees | N/A |
iX Biopharma Ltd., a specialty pharmaceutical and nutraceutical company, develops, manufactures, and commercializes therapies for the treatment of acute and breakthrough pain, and other health conditions in Singapore, Europe, the United States, China, and Australia. The company operates through Specialty Pharmaceutical and Nutraceutical segments. Its lead product candidate is Wafermine, a sublingual ketamine oral wafer for the treatment of acute moderate to severe pain, as well as for depression. The company also offers Xativa, a sublingual cannabidiol wafer for the treatment of anxiety, chronic pain, neuropathic pain, cancer pain, and insomnia; BnoX, a sublingual buprenorphine wafer for the management of moderate to severe pain; and Wafesil and Silcap for the treatment of male erectile dysfunction. In addition, it offers LumeniX, a sublingual glutathione wafer for skin brightening and immunity; WafeRest for the alleviating jetlag and promotion of sleep; and SL-NAD+ supplements product. Further, the company develops Dexmedetomidine for agitation in dementia patients; Dronabinol for chemotherapy induced nausea, vomiting, and anorexia associated with weight loss in patients with HIV/AIDS.; Apomorphine to treat the motor symptoms of Parkinson's Disease; and IXB-321, a vaccine delivery platform. Additionally, it promotes and markets nutritional and supplements products through pharmacies and health food shops, JD and Tmall e-commerce platforms in China, as well as through online store; develops and commercializes of nutraceutical products; and provides laboratory services. iX Biopharma Ltd. was incorporated in 2004 and is headquartered in Singapore.
Q&A For iX Biopharma Ltd. Stock
What is a current 42C.SI stock price?
iX Biopharma Ltd. 42C.SI stock price today per share is 0.04 SGD.
How to purchase iX Biopharma Ltd. stock?
You can buy 42C.SI shares on the SES exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for iX Biopharma Ltd.?
The stock symbol or ticker of iX Biopharma Ltd. is 42C.SI.
Which industry does the iX Biopharma Ltd. company belong to?
The iX Biopharma Ltd. industry is Drug Manufacturers-Specialty & Generic.
How many shares does iX Biopharma Ltd. have in circulation?
The max supply of iX Biopharma Ltd. shares is 768.32M.
What is iX Biopharma Ltd. Price to Earnings Ratio (PE Ratio)?
iX Biopharma Ltd. PE Ratio is now.
What was iX Biopharma Ltd. earnings per share over the trailing 12 months (TTM)?
iX Biopharma Ltd. EPS is -0.01 SGD over the trailing 12 months.
Which sector does the iX Biopharma Ltd. company belong to?
The iX Biopharma Ltd. sector is Healthcare.